

The present disclosure is directed to, among other things, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), which is a voltage-gated potassium channel opener, for use in a method of treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved means of administration of Compound A.